Pleioflow Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$1.74M
- Investors
-
2
Pleioflow General Information
Description
Developer of medical device designed for people fighting cardiovascular disease. The company utilizes pulsating balloon technology to augment blood flow into and salvage critical organs, in the clinical applications of cardiac arrest, severe heart failure, stroke, diabetes, and low cardiac output acute kidney injury, enabling doctors to significantly improve the current management of patients by preventing renal failure in both cardiac surgery and post-myocardial infarction patients.
Contact Information
Website
www.pleioflow.comCorporate Office
- 51 Stanton Road, Stapenhill
- Staffordshire
- Burton-On-Trent DE15 9RP
- England, United Kingdom
Corporate Office
- 51 Stanton Road, Stapenhill
- Staffordshire
- Burton-On-Trent DE15 9RP
- England, United Kingdom
Pleioflow Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 17-Jan-2022 | $1.74M | Completed | Clinical Trials - General | ||
| 4. Later Stage VC (Series C) | 27-Jul-2021 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series B) | 30-Oct-2020 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 31-Dec-2019 | $943K | $6.24M | Completed | Clinical Trials - General | |
| 1. Corporate | 10-Jun-2019 | $5.3M | $5.3M | Completed | Startup |
Pleioflow Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B Preferred Shares | ||||||||
| B Preferred Shares | ||||||||
| B Preferred Shares | 752,000 | $0.000675 | $2.02 | $2.02 | 1x | $2.02 | 23.96% | |
| B Preferred Shares | 720,000 | $0.000675 | $1.35 | $1.35 | 1x | $1.35 | 22.94% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Pleioflow Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pleioflow Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pleioflow Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Genesis Ventures (Greece) | Venture Capital | Minority | ||
| Olympic Investments | Venture Capital | Minority |
Pleioflow FAQs
-
When was Pleioflow founded?
Pleioflow was founded in 2018.
-
Where is Pleioflow headquartered?
Pleioflow is headquartered in Burton-On-Trent, United Kingdom.
-
What is the size of Pleioflow?
Pleioflow has 2 total employees.
-
What industry is Pleioflow in?
Pleioflow’s primary industry is Therapeutic Devices.
-
Is Pleioflow a private or public company?
Pleioflow is a Private company.
-
What is the current valuation of Pleioflow?
The current valuation of Pleioflow is .
-
What is Pleioflow’s current revenue?
The current revenue for Pleioflow is .
-
How much funding has Pleioflow raised over time?
Pleioflow has raised $10.7M.
-
Who are Pleioflow’s investors?
Genesis Ventures (Greece) and Olympic Investments have invested in Pleioflow.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
